Minireview: Update on incretin biology: Focus on glucagon-like peptide-1

Endocrinology

Volumn 151, Issue 5, 2010, Pages 1984-1989

  Brubaker, Patricia L ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CALCITONIN; EXENDIN 4; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; INCRETIN; LIRAGLUTIDE; SITAGLIPTIN; VILDAGLIPTIN; ANTIDIABETIC AGENT; GLUCAGON RECEPTOR;

CALCITONIN BLOOD LEVEL; CELL GROWTH; HUMAN; IMMUNOMODULATION; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RELEASE; NEUROPROTECTION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PANCREAS ISLET BETA CELL; PANCREATITIS; PRIORITY JOURNAL; SHORT SURVEY; THYROID CANCER; ANIMAL; APOPTOSIS; CYTOLOGY; DRUG EFFECT; DRUG POTENTIATION; METABOLISM; REVIEW;

ANIMALS; APOPTOSIS; DIABETES MELLITUS, TYPE 2; GLUCAGON-LIKE PEPTIDE 1; HUMANS; HYPOGLYCEMIC AGENTS; INCRETINS; INSULIN-SECRETING CELLS; RECEPTORS, GLUCAGON;

EID: 77953160144     PISSN: 00137227     EISSN: 00137227     Source Type: Journal    
DOI: 10.1210/en.2010-0115     Document Type: Short Survey

References (51)

1. Baggio LL, Drucker DJ 2007 Biology of incretins: GLP-1 and GIP. Gastroenterology 132:2131-2157
2. Nauck MA 2009 Unraveling the science of incretin biology. Am J Med 122:S3-S10
3. Holst JJ, Vilsbøll T, Deacon CF 2009 The incretin system and its role in type 2 diabetes mellitus. Mol Cell Endocrinol 297:127-136
4. Brubaker PL 2007 Incretin-based therapies: mimetics versus protease inhibitors. Trends Endocrinol Metab 18:240-245
5. Lovshin JA, Drucker DJ 2009 Incretin-based therapies for type 2 diabetes mellitus. Nat Rev Endocrinol 5:262-269
6. Knudsen LB, Kiel D, Teng M, Behrens C, Bhumralkar D, Kodra JT, Holst JJ, Jeppesen CB, Johnson MD, de Jong JC, Jorgensen AS, Kercher T, Kostrowicki J, Madsen P, Olesen PH, Petersen JS, Poulsen F, Sidelmann UG, Sturis J, Truesdale L, May J, Lau J 2007 Small-molecule agonists for the glucagon-like peptide 1 receptor. Proc Natl Acad Sci USA 104:937-942
7. Chen D, Liao J, Li N, Zhou C, Liu Q, Wang G, Zhang R, Zhang S, Lin L, Chen K, Xie X, Nan F, Young AA, Wang MW 2007 A nonpeptidic agonist of glucagon-like peptide 1 receptors with efficacy in diabetic db/db mice. Proc Natl Acad Sci USA 104:943-948
8. Teng M, Johnson MD, Thomas C, Kiel D, Lakis JN, Kercher T, Aytes S, Kostrowicki J, Bhumralkar D, Truesdale L, May J, Sidelman U, Kodra JT, Jørgensen AS, Olesen PH, de Jong JC, Madsen P, Behrens C, Pettersson I, Knudsen LB, Holst JJ, Lau J 2007 Small molecule agoallosteric modulators of the human glucagon-like peptide-1 (hGLP-1) receptor. Bioorg Med Chem Lett 17:5472-5478
9. Edfalk S, Steneberg P, Edlund H 2008 Gpr40 is expressed in enteroendocrine cells and mediates FFA stimulation of incretin secretion. Diabetes 57:2280-2287
10. Hirasawa A, Tsumaya K, Awaji T, Katsuma S, Adachi T, Yamada M, Sugimoto Y, Miyazaki S, Tsujimoto G 2005 Free fatty acids regulate gut incretin glucagon-like peptide-1 secretion through GPR120. Nat Med 11:90-94 (Pubitemid 40215843)
11. Regard JB, Sato IT, Coughlin SR 2008 Anatomical profiling of G protein-coupled receptor expression. Cell 135:561-571
12. Chu ZL, Carroll C, Alfonso J, Gutierrez V, He H, Lucman A, Pedraza M, Mondala H, Gao H, Bagnol D, Chen R, Jones RM, Behan DP, Leonard J 2008 A role for intestinal endocrine cell-expressed g protein-coupled receptor 119 in glycemic control by enhancing glucagon-like peptide-1 and glucose-dependent insulinotropic peptide release. Endocrinology 149:2038-2047
13. Lauffer LM, Iakoubov R, Brubaker PL 2009 GPR119 is essential for oleoylethanolamide-induced glucagon-like peptide-1 secretion from the intestinal enteroendocrine L-cell. Diabetes 58:1058-1066
14. Thomas C, Gioiello A, Noriega L, Strehle A, Oury J, Rizzo G, Macchiarulo A, Yamamoto H, Mataki C, Pruzanski M, Pellicciari R, Auwerx J, Schoonjans K 2009 TGR5-mediated bile acid sensing controls glucose homeostasis. Cell Metab 10:167-177
15. Evans KA, Budzik BW, Ross SA, Wisnoski DD, Jin J, Rivero RA, Vimal M, Szewczyk GR, Jayawickreme C, Moncol DL, Rimele TJ, Armour SL, Weaver SP, Griffin RJ, Tadepalli SM, Jeune MR, Shearer TW, Chen ZB, Chen L, Anderson DL, Becherer JD, De Los Frailes M, Colilla FJ 2009 Discovery of 3-aryl-4- isoxazolecarboxamides as TGR5 receptor agonists. J Med Chem 52:7962-7965
16. Ban K, Noyan-Ashraf MH, Hoefer J, Bolz SS, Drucker DJ, Husain M2008 Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and -independent pathways. Circulation 117:2340-2350
17. Sokos GG, Nikolaidis LA, Mankad S, Elahi D, Shannon RP 2006 Glucagon-like peptide-1 infusion improves left ventricular ejection fraction and functional status in patients with chronic heart failure. J Card Fail 12:694-699
18. Sokos GG, Bolukoglu H, German J, Hentosz T, Magovern Jr GJ, Maher TD, Dean DA, Bailey SH, Marrone G, Benckart DH, Elahi D, Shannon RP 2007 Effect of glucagon-like peptide-1 (GLP-1) on glycemic control and left ventricular function in patients undergoing coronary artery bypass grafting. Am J Cardiol 100:824-829
19. Knudsen LB, Pridal L 1996 Glucagon-like peptide-1-(9-36) amide is a major metabolite of glucagon-like peptide-1-(7-36) amide after in vivo administration to dogs, and it acts as an antagonist on the pancreatic receptor. Eur J Pharmacol 318:429-435
20. Nikolaidis LA, Elahi D, Shen YT, Shannon RP 2005 Active metabolite of GLP-1 mediates myocardial glucose uptake and improves left ventricular performance in conscious dogs with dilated cardiomyopathy. Am J Physiol Heart Circ Physiol 289:H2401-H2408
21. Dupré J, Behme MT, McDonald TJ 2004 Exendin-4 normalized postcibal glycemic excursions in type 1 diabetes. J Clin Endocrinol Metab 89:3469-3473 (Pubitemid 38951922)
22. Kielgast U, Holst JJ, Madsbad S 2009 Treatment of type 1 diabetic patients with glucagon-like peptide-1 (GLP-1) and GLP-1R agonists. Curr Diabetes Rev 5:266-275
23. Hadjiyanni I, Baggio LL, Poussier P, Drucker DJ 2008 Exendin-4 modulates diabetes onset in nonobese diabetic mice. Endocrinology 149:1338-1349
24. Suarez-Pinzon WL, Power RF, Yan Y, Wasserfall C, Atkinson M, Rabinovitch A 2008 Combination therapy with glucagon-like peptide-1 and gastrin restores normoglycemia in diabetic NOD mice. Diabetes 57:3281-3288
25. Kim SJ, Nian C, Doudet DJ, McIntosh CH 2009 Dipeptidyl peptidase IV inhibition with MK0431 improves islet graft survival in diabetic NOD mice partially via T-cell modulation. Diabetes 58:641-651
26. Perry T, Holloway HW, Weerasuriya A, Mouton PR, Duffy K, Mattison JA, Greig NH 2007 Evidence of GLP-1-mediated neuro-protection in an animal model of pyridoxine-induced peripheral sensory neuropathy. Exp Neurol 203:293-301
27. Bertilsson G, Patrone C, Zachrisson O, Andersson A, Dannaeus K, Heidrich J, Kortesmaa J, Mercer A, Nielsen E, Rönnholm H, Wikström L 2008 Peptide hormone exendin-4 stimulates subventricular zone neurogenesis in the adult rodent brain and induces recovery in an animal model of Parkinson's disease. J Neurosci Res 86:326-338
28. Martin B, Golden E, Carlson OD, Pistell P, Zhou J, Kim W, Frank BP, Thomas S, Chadwick WA, Greig NH, Bates GP, Sathasivam K, Bernier M, Maudsley S, Mattson MP, Egan JM 2009 Exendin-4 improves glycemic control, ameliorates brain and pancreatic pathologies, and extends survival in a mouse model of Huntington's disease. Diabetes 58:318-328
29. Jin HY, Liu WJ, Park JH, Baek HS, Park TS2009 Effect of dipeptidyl peptidase-IV (DPP-IV) inhibitor (vildagliptin) on peripheral nerves in streptozotocin-induced diabetic rats. Arch Med Res 40:536-544
30. Klöppel G, Löhr M, Habich K, Oberholzer M, Heitz PU 1985 Islet pathology and the pathogenesis of type 1 and type 2 diabetes mellitus revisited. Surv Synth Pathol Res 4:110-125
31. Butler AE, Janson J, Bonner-Weir S, Ritzel R, Rizza RA, Butler PC 2003 β-Cell deficit and increased β-cell apoptosis in humans with type 2 diabetes. Diabetes 52:102-110
32. Brubaker PL, Drucker DJ 2004 Minireview: glucagon-like peptides regulate cell proliferation and apoptosis in the pancreas, gut, and central nervous system. Endocrinology 145:2653-2659
33. Van Assche FA, Aerts L, De Prins F 1978 A morphological study of the endocrine pancreas in human pregnancy. Br J Obstet Gynaecol 85:818-820 (Pubitemid 9009998)
34. Meier JJ, Butler AE, Galasso R, Rizza RA, Butler PC 2006 Increased islet β cell replication adjacent to intrapancreatic gastrinomas in humans. Diabetologia 49:2689-2696
35. Meier JJ, Lin JC, Butler AE, Galasso R, Martinez DS, Butler PC 2006 Direct evidence of attempted β cell regeneration in an 89-year-old patient with recent-onset type 1 diabetes. Diabetologia 49:1838-1844
36. Menge BA, Tannapfel A, Belyaev O, Drescher R, Müller C, Uhl W, Schmidt WE, Meier JJ 2008 Partial pancreatectomy in adult humans does not provoke β-cell regeneration. Diabetes 57:142-149
37. Farilla L, Bulotta A, Hirshberg B, Li Calzi S, Khoury N, Noushmehr H, Bertolotto C, Di Mario U, Harlan DM, Perfetti R 2003 Glucagon-like peptide 1 inhibits cell apoptosis and improves glucose responsiveness of freshly isolated human islets. Endocrinology 144:5149-5158
38. Ahmad SR, Swann J 2008 Exenatide and rare adverse events. N Engl J Med 358:1970-1971
39. Garber A, Henry R, Ratner R, Garcia-Hernandez PA, Rodriguez-Pattzi H, Olvera-Alvarez I, Hale PM, Zdravkovic M, Bode B 2009 Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial. Lancet 373:473-481
40. Raufman JP, Singh L, Singh G, Eng J 1992 Truncated glucagon-like peptide-1 interacts with exendin receptors on dispersed acini from guinea pig pancreas. Identification of a mammalian analogue of the reptilian peptide exendin-4. J Biol Chem 267:21432-21437
41. Koehler JA, Baggio LL, Lamont BJ, Ali S, Drucker DJ 2009 Glucagon-like peptide-1 receptor activation modulates pancreatitis-associated gene expression but does not modify the susceptibility to experimental pancreatitis in mice. Diabetes 58:2148-2161
42. Dore DD, Seeger JD, Arnold Chan K 2009 Use of a claims-based active drug safety surveillance system to assess the risk of acute pancreatitis with exenatide or sitagliptin compared to metformin or glyburide. Curr Med Res Opin 25:1019-1027
43. Matveyenko AV, Dry S, Cox HI, Moshtaghian A, Gurlo T, Galasso R, Butler AE, Butler PC 2009 Beneficial endocrine but adverse exocrine effects of sitagliptin in the human islet amyloid polypeptide transgenic rat model of type 2 diabetes: interactions with metformin. Diabetes 58:1604-1615
44. Nachnani JS, Bulchandani DG, Nookala A, Herndon B, Molteni A, Pandya P, Taylor R, Quinn T, Weide L, Alba LM 2010 Biochemical and histological effects of exendin-4 (exenatide) on the rat pancreas. Diabetologia 53:153-159
45. Parola A 2009 FDA advisory committee non-clinical briefing document. New drug application, 22-341. Silver Spring, MD: Food and Drug Administration
46. Lim GE, Huang GJ, Flora N, LeRoith D, Rhodes CJ, Brubaker PL 2009 Insulin regulates glucagon-like peptide-1 secretion from the enteroendocrine L cell. Endocrinology 150:580-591
47. Rask E, Olsson T, Soderberg S, Johnson O, Secki J, Holst JJ, Ahren B 2001 Impaired incretin response after a mixed meal is associated with insulin resistance in nondiabetic men. Diab Care 24:1640-1645 (Pubitemid 33716463)
48. Edwards CM, Todd JF, Mahmoudi M, Wang Z, Wang RM, Ghatei MA, Bloom SR 1999 Glucagon-like peptide 1 has a physiological role in the control of postprandial glucose in humans: studies with the antagonist exendin 9-39. Diabetes 48:86-93
49. Schäfer SA, Tschritter O, Machicao F, Thamer C, Stefan N, Gallwitz B, Holst JJ, Dekker JM, 't Hart LM, Nijpels G, van Haeften TW, Häring HU, Fritsche A 2007 Impaired glucagon-like peptide-1-induced insulin secretion in carriers of transcription factor 7-like 2 (TCF7L2) gene polymorphisms. Diabetologia 50:2443-2450
50. Pilgaard K, Jensen CB, Schou JH, Lyssenko V, Wegner L, Brøns C, Vilsbøll T, Hansen T, Madsbad S, Holst JJ, Vølund A, Poulsen P, Groop L, Pedersen O, Vaag AA 2009 The T allele of rs7903146 TCF7L2is associated with impaired insulinotropic action of incretin hormones, reduced 24 h profiles of plasma insulin and glucagon, and increased hepatic glucose production in young healthy men. Diabetologia 52:1298-1307
51. Shu L, Matveyenko AV, Kerr-Conte J, Cho JH, McIntosh CH, Maedler K 2009 Decreased TCF7L2 protein levels in type 2 diabetes mellitus correlate with downregulation of GIP- and GLP-1 receptors and impaired β-cell function. Hum Mol Genet 18:2388-2399